Publication date: Jul 28, 2025

The novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted a global health crisis, necessitating diverse therapeutic strategies. This review explores the integration of Traditional Chinese Medicine (TCM) with conventional medicine in managing COVID-19, highlighting the potential synergistic effects of combining these approaches. TCM formulations such as Lian Hua Qing Wen capsules and Shu Feng Jie Du capsules have shown promise in alleviating symptoms and enhancing recovery rates in COVID-19 patients through their antiviral, anti-inflammatory, and immunomodulatory properties. Key components such as glycyrrhizin, quercetin, and resveratrol, along with fungal, animal, and mineral preparations, contribute to the therapeutic efficacy of TCM. Some individual polyphenolics, found in TCM formulations, significantly contribute to anti-SARS-CoV-2 effect: their EC50 values range from 4. 5 μmol/L (baicalein) to 83. 4 μmol/L (quercetin), depending on the types of cells used and the treatment period. The review emphasizes the importance of rigorous scientific research to validate the effectiveness and safety of TCM treatments and the need for standardized protocols to ensure their consistent use. The quality and safety of Chinese herbal products still pose significant challenges that should be considered during their production and use. The integration of TCM with conventional medical practices offers a holistic approach to patient care, addressing the multifaceted pathophysiology of COVID-19 and enhancing overall treatment outcomes. Continued international collaborations and interdisciplinary research are essential to bridge the gap between traditional and modern medicine, fostering a more inclusive healthcare system.

Semantics

Original Article